Literature DB >> 21190422

Electroporation therapy for T1 and T2 oral tongue cancer.

Fredrik J Landström1, Christer O S Nilsson, Johan A Reizenstein, Kent Nordqvist, Gun-Britt Adamsson, A Lennart Löfgren.   

Abstract

CONCLUSION: Electroporation therapy appears to be a safe treatment achieving excellent local tumor control and very good functional results in our study and it should be further clinically evaluated.
OBJECTIVES: The objectives of this study were to assess local tumor control, survival, and effects on speech and eating after treatment of tongue cancer with electroporation therapy, a new local therapeutic modality. In this approach intracellular accumulation of a chemotherapeutic agent is achieved by using a locally applied electrical field.
METHODS: Fifteen patients with primary T1 and T2 oral tongue cancer were treated with electroporation therapy with intratumorally administered bleomycin. Postoperative radiotherapy was performed when the tumor infiltration was 5 mm or more. The follow-up time was 24 months for the surviving patients and 20.4 months overall. The effects on eating and speech were assessed using the PSS-HN scale and voice recordings.
RESULTS: No local recurrence was recorded in any patient during the follow-up. Three patients died, two from progressive regional disease. Of the 12 surviving patients, 2 patients had regional recurrence and 10 patients including the 5 patients treated with EPT alone were tumor-free both locally and regionally at the last follow-up. The functional outcome for speech and eating were very good.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190422     DOI: 10.3109/00016489.2010.541937

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  7 in total

1.  Electrochemotherapy: a well-accepted palliative treatment by patients with head and neck tumours.

Authors:  B Pichi; R Pellini; A DE Virgilio; G Spriano
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-06       Impact factor: 2.124

2.  Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma.

Authors:  Nicola Mozzillo; Corrado Caracò; Stefano Mori; Gianluca Di Monta; Gerardo Botti; Paolo A Ascierto; Corradina Caracò; Luigi Aloj
Journal:  J Transl Med       Date:  2012-06-22       Impact factor: 5.531

3.  Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.

Authors:  Gianluca Di Monta; Corrado Caracò; Ester Simeone; Antonio Maria Grimaldi; Ugo Marone; Massimiliano Di Marzo; Vito Vanella; Lucia Festino; Marco Palla; Stefano Mori; Nicola Mozzillo; Paolo Antonio Ascierto
Journal:  J Transl Med       Date:  2017-04-26       Impact factor: 5.531

4.  Calcium electroporation for recurrent head and neck cancer: A clinical phase I study.

Authors:  Christina Caroline Plaschke; Julie Gehl; Helle Hjorth Johannesen; Barbara Malene Fischer; Andreas Kjaer; Anne Fog Lomholt; Irene Wessel
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-01-03

Review 5.  Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review.

Authors:  Primož Strojan; Aleš Grošelj; Gregor Serša; Christina Caroline Plaschke; Jan B Vermorken; Sandra Nuyts; Remco de Bree; Avraham Eisbruch; William M Mendenhall; Robert Smee; Alfio Ferlito
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

Review 6.  Electrochemotherapy: from the drawing board into medical practice.

Authors:  Damijan Miklavčič; Barbara Mali; Bor Kos; Richard Heller; Gregor Serša
Journal:  Biomed Eng Online       Date:  2014-03-12       Impact factor: 2.819

7.  Endoscopic electrochemotherapy for esophageal cancer: a phase I clinical study.

Authors:  Charlotte Egeland; Lene Baeksgaard; Helle Hjorth Johannesen; Johan Löfgren; Christina Caroline Plaschke; Lars Bo Svendsen; Julie Gehl; Michael Patrick Achiam
Journal:  Endosc Int Open       Date:  2018-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.